The reduction in insulin use in 2021 was associated with a rise in the use of SZC, for which there were 66 treatment initiations, (varying in length with a total of 208 single administrations in 58 patients) for the acute treatment of hyperkalaemia (Fig. 3). Here, INS is linked to Hyperkalemia.